Publication related to RSI or an RSI staff member

Toxicity testing in the 21st century: bringing the vision to life.

In 2007, the U.S. National Academy of Sciences released a report, Toxicity Testing in the 21st Century: A Vision and a Strategy, that envisions a not-so-distant future in which virtually all routine toxicity testing would be conducted in human cells or cell lines in vitro by evaluating cellular responses in a suite of toxicity pathway assays using high-throughput tests, that could be implemented with robotic assistance. Risk assessment based on results of these types of tests would shift towards the avoidance of significant perturbations of these pathways in exposed human populations. Dose-response modeling of perturbations of pathway function would be organized around computational systems biology models of the circuitry underlying each toxicity pathway. In vitro to in vivo extrapolations would rely on pharmacokinetic models to predict human blood and tissue concentrations under specific exposure conditions. All of the scientific tools needed to affect these changes in toxicity testing practices are either currently available or in an advanced state of development. A broad scientific discussion of this new vision for the future of toxicity testing is needed to motivate a departure from the traditional high dose animal-based toxicological tests, with its attendant challenges for dose and species extrapolation, towards a new approach more firmly grounded in human biology. The present paper, and invited commentaries on the report that will appear in Toxicological Sciences over the next year, are intended to initiate a dialog to identify challenges in implementing the vision and address obstacles to change.

Authors

  • Andersen, Melvin E, Andersen ME, Computational Biology Division, Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709, USA. MAndersen@TheHamner.org

  • Krewski, Daniel, Krewski D,

YEAR OF PUBLICATION: 2009
SOURCE: Toxicol Sci. 2009 Feb;107(2):324-30. doi: 10.1093/toxsci/kfn255. Epub 2008 Dec 12.
JOURNAL TITLE ABBREVIATION: Toxicol Sci
JOURNAL TITLE: Toxicological sciences : an official journal of the Society of Toxicology
ISSN: 1096-0929 (Electronic) 1096-0929 (Linking)
VOLUME: 107
ISSUE: 2
PAGES: 324-30
PLACE OF PUBLICATION: United States
ABSTRACT:
In 2007, the U.S. National Academy of Sciences released a report, Toxicity Testing in the 21st Century: A Vision and a Strategy, that envisions a not-so-distant future in which virtually all routine toxicity testing would be conducted in human cells or cell lines in vitro by evaluating cellular responses in a suite of toxicity pathway assays using high-throughput tests, that could be implemented with robotic assistance. Risk assessment based on results of these types of tests would shift towards the avoidance of significant perturbations of these pathways in exposed human populations. Dose-response modeling of perturbations of pathway function would be organized around computational systems biology models of the circuitry underlying each toxicity pathway. In vitro to in vivo extrapolations would rely on pharmacokinetic models to predict human blood and tissue concentrations under specific exposure conditions. All of the scientific tools needed to affect these changes in toxicity testing practices are either currently available or in an advanced state of development. A broad scientific discussion of this new vision for the future of toxicity testing is needed to motivate a departure from the traditional high dose animal-based toxicological tests, with its attendant challenges for dose and species extrapolation, towards a new approach more firmly grounded in human biology. The present paper, and invited commentaries on the report that will appear in Toxicological Sciences over the next year, are intended to initiate a dialog to identify challenges in implementing the vision and address obstacles to change.
LANGUAGE: eng
DATE OF PUBLICATION: 2009 Feb
DATE OF ELECTRONIC PUBLICATION: 20081212
DATE COMPLETED: 20090311
DATE REVISED: 20250124
MESH DATE: 2009/03/12 09:00
EDAT: 2008/12/17 09:00
STATUS: MEDLINE
PUBLICATION STATUS: ppublish
LOCATION IDENTIFIER: 10.1093/toxsci/kfn255 [doi]
OWNER: NLM

Related RSI Experts

Daniel Krewski

Chief Risk Scientist

Dr. Daniel Krewski is Chief Risk Scientist and co-founder of Risk Sciences International (RSI), a firm established in 2006 to bring evidence-based, multidisciplinary expertise to the challenge of understanding, managing, and communicating risk. As RSI’s inaugural CEO and long-time scientific...
Read More about Daniel Krewski